Drug Type Recombinant protein |
Synonyms AIM, ApoA1 Milano, r-ApoA-I Milano + [5] |
Target |
Action stimulants |
Mechanism APOA1 stimulants(Apolipoprotein A-I stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 2 | Canada | 03 Dec 2015 | |
Atherosclerosis | Phase 2 | Czechia | 03 Dec 2015 | |
Atherosclerosis | Phase 2 | Hungary | 03 Dec 2015 | |
Atherosclerosis | Phase 2 | Netherlands | 03 Dec 2015 | |
Atherosclerosis | Phase 2 | Poland | 03 Dec 2015 | |
Acute Coronary Syndrome | Phase 2 | United States | - | |
Acute Coronary Syndrome | Phase 2 | Canada | - | |
Acute Coronary Syndrome | Phase 2 | Czechia | - | |
Acute Coronary Syndrome | Phase 2 | Hungary | - | |
Acute Coronary Syndrome | Phase 2 | Netherlands | - |
Phase 1/2 | 122 | zpdmefdfcx(accesgaxam) = esiryjwdkh yiqcxnwwcc (isbxqesacy ) View more | Negative | 01 Sep 2018 | |||
Placebo | zpdmefdfcx(accesgaxam) = nnnaosdyqo yiqcxnwwcc (isbxqesacy ) View more | ||||||
Phase 1/2 | 126 | (MDCO-216) | mbgklsnikm(dtfghycdmv) = dkgpwegpas gwkqhgzjhz (jtgfqgsafl, 0.386) View more | - | 13 Jul 2017 | ||
Placebo (Placebo) | mbgklsnikm(dtfghycdmv) = yvtanqujip gwkqhgzjhz (jtgfqgsafl, 0.382) View more |